Login to Your Account



At 'PRESENT,' Galena still blinded to data as operational review of Neuvax trial underway

By Marie Powers
News Editor

Saturday, July 9, 2016

Officials at Galena Biopharma Inc. are still in the dark on data from the phase III PRESENT trial of cancer vaccine Neuvax, company president and CEO Mark Schwartz revealed Friday on a conference call with analysts.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription